Aytu BioPharma Q1 net income $1.5M; promotes Ryan Selhorn as CFO

AYTU BIOPHARMA, INC

2025-Q1 EPS reported -$0.15 revenue$16,574,000

Net income of $1.5M vs net loss of $8.1M YoY; diluted EPS $0.15 loss vs $1.48 loss.
Adjusted EBITDA $1.9M, down 21% from $2.4M; cash stable at $20.1M.
ADHD Portfolio net revenue $15.3M (+1% YoY); Pediatric Portfolio up 54% sequentially.
CFO Mark Oki terminated; Ryan Selhorn appointed CFO with base salary $400K.
Board separated Chairman/CEO roles; John Donofrio appointed Chairman.

item 2.02 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ryan Selhorn

Chief Financial Officer, Corporate Secretary and Treasurer

AYTU · AYTU BIOPHARMA, INC

Effective: 2024-11-11
Filed: November 13, 2024, 6:59 PM ET

On November 11, 2024, the board of directors of the Company (the " Board ") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.

Departed

Mark K. Oki

Chief Financial Officer

AYTU · AYTU BIOPHARMA, INC

Effective: 2024-11-11
Successor: Ryan Selhorn
Filed: November 13, 2024, 6:59 PM ET

On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ryan Selhorn was appointed as Chief Financial Officer, Corporate Secretary and Treasurer at AYTU BIOPHARMA, INC.

Action: appointed
Role: Chief Financial Officer, Corporate Secretary and Treasurer

Exact text from the filing

On November 11, 2024, the board of directors of the Company (the " Board ") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark K. Oki was terminated as Chief Financial Officer at AYTU BIOPHARMA, INC.

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.

View on SEC.gov

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001437749-24-034898

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.